eClinicalMed Profile Banner
eClinicalMedicine – The Lancet Discovery Science Profile
eClinicalMedicine – The Lancet Discovery Science

@eClinicalMed

Followers
8K
Following
2K
Media
2K
Statuses
7K

Gold open access clinical journal, part of @TheLancet Discovery Science, influencing clinical practice and strengthening health. IF: 10·0; CiteScore: 17·0.

London UK - Boston USA
Joined May 2018
Don't wanna be here? Send us removal request.
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
14 days
📢July issue now online featuring #BreastCancer, #RSV, #COVID19, #CrohnsDisease, #antimicrobial use, #osteoporosis, and much more with our editorial on whole-genome sequencing for newborns. …all available #OpenAccess❗️. Read more here: Attribution: Getty
Tweet media one
1
0
3
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
2 hours
Effects of therapeutic interventions on long COVID: a meta-analysis of randomized controlled trials. Advocates for updated clinical guidelines integrating multimodal therapies and underscores the urgency of large-scale trials to optimise dosing. #LongCOVID
Tweet media one
0
2
1
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
2 days
Disease accumulation and distribution across lifespan in Swedish centenarians and non-centenarians: a nationwide study. Suggests preserved homeostatic capacity and sustained functional integrity despite cumulative physiological stressors in #centenarians.
Tweet media one
0
0
2
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
2 days
RT @aipulserx: How can machine learning models predict which lung cancer surgery patients will develop life-threatening postoperative pulmo….
0
1
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
2 days
RT @Thoracic_PubMed: .@eClinicalMed.📚 Systematic Review & Meta-Analysis of 11 RCTs (Phase II/III) .👥 3,228 patients (67% male) with advanc….
0
1
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
5 days
Factors influencing prevalence and death rate of #COPD: a study of 201 countries and regions from 1990 to 2021. Various factors (tobacco, atmospheric pollution, biomass cooking, temperature, social factors, and comorbidities) significantly influence COPD.
Tweet media one
0
0
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
5 days
RT @LSchwingshackl: Association between substituting macronutrients and all-cause mortality: a network meta-analysis of prospective obser….
Tweet card summary image
thelancet.com
Our results provide practical knowledge for public health professionals and can inform upcoming dietary guidelines. The beneficial association of increasing PUFA (both n-3 and n-6) and (plant-) MUFA...
0
3
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
6 days
RT @BreastOncPubMed: .@eClinicalMed.Multicenter phase 2 trial NJMU-BC01 (n=74). De-escalated neoadjuvant nab-paclitaxel + pyrotinib + trast….
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
National Natural Science Foundation of China and Natural Science Foundation of Jiangsu Province.
0
1
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
7 days
RT @greg_folkers: .@eClinicalMed : Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality o….
0
1
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
7 days
Exploring potential associations between GLP-1RAs and depressive disorders: a PV study based on FAERS and VigiBase data. Identified a semaglutide-specific SDR for depressive disorders across both databases, while liraglutide and tirzepatide showed no SDRs.
Tweet media one
0
1
1
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
8 days
RT @TheLancet: 📢 Launch of The Lancet Countdown on Health and Plastics. On August 4, a new report will offer an up-to-date assessment of th….
Tweet card summary image
tessforum.org
0
10
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
8 days
RT @TheLancetOncol: 📢Our Aug issue is now live: 📊Original research #prostatecancer, contraceptive use and #liverca….
0
4
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
9 days
Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: a phase 2 study. Obinutuzumab is active as single-agent induction and maintenance in patients with r/r Waldenström #macroglobulinaemia with manageable toxicity.
Tweet media one
0
0
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
9 days
RT @cancer_K2A: 🚨 New RCT 📰 in @eClinicalMed.Online #Mindfulness intervention ⬇️'s fear of cancer recurrence (#FCR), anxiety & depression.A….
0
7
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
9 days
RT @mangelini_med: ❓What outcomes matter most in genital gender-affirming surgery (gGAS) research? . For years, studies on gGAS have report….
0
1
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
9 days
RT @ouedraogo_adama: We are delighted to share with you our new study on intimate partner violence during pregnancy (IPV-DP) in 57 countrie….
Tweet card summary image
thelancet.com
Despite the implementation of numerous development programs aimed at reducing violence against women in LMICs in recent decades, IPVDP remains high in some countries and has even increased in others....
0
1
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
12 days
Risk of clinical events in virologically suppressed people with #HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation. Suggests that virologically suppressed PWH can be safely switched to a two-drug regimen.
Tweet media one
0
0
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
13 days
RT @LancetGastroHep: Ahead of #WorldHepatitisDay on July 28th, we've published a collection of viral hepatitis-related content. Follow….
0
4
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
13 days
RT @LjiljanaMarina: Happy to have had the chance to collaborate with @IrinaBancos and David on this important project! 🙌.Tailoring mentorsh….
0
4
0
@eClinicalMed
eClinicalMedicine – The Lancet Discovery Science
15 days
RT @lymphomahub: 📝Phase II Epi-RCHOP findings published in @eClinicalMed found that tazemetostat + R-CHOP achieved an estimated PFS and OS….
0
2
0